Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast CancerXian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, et al.
BMC Cancer|March 16, 2019
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysisArturo B Ramirez, Raksha Bhat, Debashish Sahay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come, Aman U Buzdar, Carlos L Arteaga, et al.
Breast Cancer Research and Treatment|March 26, 2018
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancerRaksha R Bhat, Puja Yadav, Debashish Sahay, et al.
Cell Research|May 31, 2014
An epigenomic approach to therapy for tamoxifen-resistant breast cancerQin Feng, Zheng Zhang, Martin J Shea, et al.
Breast Cancer Research : BCR|December 18, 2008
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotypeChanghua Zhou, Ashley M Nitschke, Wei Xiong, et al.
Journal of Cellular Physiology|August 5, 2018
AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cellsPetreena S Campbell, Nicole Mavingire, Salma Khan, et al.
British Journal of Cancer|December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Hazel Weir, Oona Delpuech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Molecular Cancer Research : MCR|March 12, 2016
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Mario Giuliano, Ilenia Migliaccio, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast CancerXian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, et al.
BMC Cancer|March 16, 2019
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysisArturo B Ramirez, Raksha Bhat, Debashish Sahay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come, Aman U Buzdar, Carlos L Arteaga, et al.
Breast Cancer Research and Treatment|March 26, 2018
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancerRaksha R Bhat, Puja Yadav, Debashish Sahay, et al.
Cell Research|May 31, 2014
An epigenomic approach to therapy for tamoxifen-resistant breast cancerQin Feng, Zheng Zhang, Martin J Shea, et al.
Breast Cancer Research : BCR|December 18, 2008
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotypeChanghua Zhou, Ashley M Nitschke, Wei Xiong, et al.
Journal of Cellular Physiology|August 5, 2018
AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cellsPetreena S Campbell, Nicole Mavingire, Salma Khan, et al.
British Journal of Cancer|December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Hazel Weir, Oona Delpuech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast CancerMothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Molecular Cancer Research : MCR|March 12, 2016
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Mario Giuliano, Ilenia Migliaccio, et al.
Pageof 20